Safety evaluation of selective RET inhibitors in patients with lung cancer: a real-world pharmacovigilance study
Selpercatinib and pralsetinib are targeted therapies for non-small cell lung cancer. However, their adverse reaction profiles remain incompletely understood. This study aims to evaluate the post-marketing adverse events (AEs) associated with selpercatinib and pralsetinib in real-world populations.